All In Biotech

Drug Trial Radar · NCT07181343

A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)

A Study to Evaluate the Pharmacokinetics of Drospirenone and Ethinyl Estradiol Tablets (Yasmin®) When Co-administered With HS-10374 Tablets

Last checked: Nov 19, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

May 28, 2025

Primary completion

Jun 17, 2025

Study completion Aug 19, 2025

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is a single-center, open-label, fixed-sequence, self-controlled clinical study to evaluate Drug-Drug Interaction Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets (Yasmin®)

Conditions

  • Psoriasis (PsO)

Interventions

  • HS-10374 tabletsDrug

    From Day 8 to Day 19, participants will orally take HS-10374 Tablets 12 mg(6 mg×2) once daily under fasting conditions

  • Drospirenone and Ethinyl Estradiol tabletsDrug

    On Day 1 and Day 14, participants will orally take one tablet of Drospirenone and Ethinylestradiol Tablets under fasting conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of PK parameters of drospirenone and ethinylestradiol when used alone or in combination with HS-10374: CmaxTime frame: up to Day 20
  2. Evaluation of PK parameters of drospirenone and ethinylestradiol when used alone or in combination with HS-10374: AUC0-tTime frame: up to Day 20
  3. Evaluation of PK parameters of drospirenone and ethinylestradiol when used alone or in combination with HS-10374: AUC0-24 hTime frame: up to Day 20
  4. Evaluation of PK parameters of drospirenone and ethinylestradiol when used alone or in combination with HS-10374: AUC0-∞Time frame: up to Day 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.